Key facts
- This page summarizes Michael Egholm's Form 4 filing for STANDARD BIOTOOLS INC. (LAB).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 06 Apr 2023, 19:02.
Michael Egholm - 04 Apr 2023 Form 4 Insider Report for STANDARD BIOTOOLS INC. (LAB)
- Reporting relationship
- President & CEO, Director
- Issuer ticker
- LAB
- Reported as of
- 04 Apr 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 06 Apr 2023, 19:02:50 UTC
- Prior SEC filing
- 21 Jun 2022
- Next SEC filing
- 05 Apr 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Michael Egholm
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Michael Egholm filed Form 4 for STANDARD BIOTOOLS INC. (LAB) on 06 Apr 2023.
Change
- Previous filing in this sequence was filed on 21 Jun 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
LAB
transaction
Common Stock
Options Exercise
- Transaction value
- $0
- Shares
- +196,512
- Change %
- +1965%
- Price
- $0.000000
- Shares after
- 206,512
- Date
- 04 Apr 2023
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
LAB
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -196,512
- Change %
- -25%
- Price
- $0.000000
- Shares after
- 589,537
- Date
- 04 Apr 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 196,512
- Exercise price
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Includes 5,000 shares of Common Stock purchased pursuant to Fluidigm Corporation (currently Standard BioTools Inc.) 2017 Employee Stock Purchase Plan ("ESPP") for the purchase period of June 1, 2022 to November 30, 2022.
Footnote F2
Each Restricted Stock Unit represents the contingent right to receive one share of LAB common stock.
Footnote F3
Restricted Stock Units vest in four equal annual installments beginning April 4, 2023.